Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Iron Trafficking Is Essential for Glioblastoma CSC Tumorigenicity

DOI: 10.1158/2159-8290.CD-RW2015-199 Published December 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • Major finding: GBM CSCs require the iron regulators transferrin receptor and ferritin to drive tumorigenesis.

  • Mechanism: Gain of an epigenetic program enhances CSC iron uptake, and STAT3–FOXM1 signaling drives CSC growth.

  • Impact: Disrupting iron flux in CSCs is a potential therapeutic strategy for the treatment of GBM.

Figure1

Glioblastoma (GBM) is the most common adult brain malignancy and, in spite of highly aggressive treatment, has a poor prognosis. The lack of treatment efficacy may be due in part to the presence of the CD133+ cancer stem-like cell (CSC) subpopulation of GBMs, which has been shown to be radioresistant and chemoresistant and can flourish in the stresses inflicted by the tumor microenvironment. These stresses are mediated in part by aberrant iron metabolism, prompting Schonberg and colleagues to investigate the role of iron regulation in the tumorigenicity of GBM CSCs. Next-generation RNA sequencing identified transferrin (TF) as the most differentially expressed gene in GBM CSCs, which secreted high levels of TF compared with non-CSCs. Epigenomic profiling revealed that TF enhancers were present in CSCs and in a cell line model of hepatocytes, suggesting that TF upregulation in CSCs is mediated by the acquisition of a liver-specific epigenetic mechanism. Consistent with these findings, iron tracing experiments showed increased unbound iron uptake in CSCs compared with non-CSCs. Expression of transferrin receptor (TfR), which mediates intracellular entry of TF-bound iron, and ferritin, which stores excess intracellular iron, was increased in a grade-dependent fashion in gliomas, in particular CSCs, and negatively correlated with patient survival. Furthermore, expression of TfR enhanced tumorsphere formation and tumor initiation, whereas knockdown of ferritin resulted in decreased CSC growth in vitro and impaired CSC tumorigenicity in vivo. Gene expression profiling revealed that this growth inhibition may be due to regulation of cell-cycle progression by ferritin and identified STAT3 as the gene most highly correlated with ferritin expression. Knockdown and rescue experiments showed that forkhead box M1 (FOXM1), a STAT3-regulated transcription factor, was critical for ferritin-mediated regulation of CSCs. Together, these results show that GBM CSC tumorigenicity is dependent on the acquisition of an epigenetic mechanism that drives iron metabolism and is potentially targetable.

Schonberg DL, Miller TE, Wu Q, Flavahan WA, Das NK, Hale JS, et al. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 2015;28:441–55.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Iron Trafficking Is Essential for Glioblastoma CSC Tumorigenicity
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Iron Trafficking Is Essential for Glioblastoma CSC Tumorigenicity
Cancer Discov December 1 2015 (5) (12) 1236; DOI: 10.1158/2159-8290.CD-RW2015-199

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Iron Trafficking Is Essential for Glioblastoma CSC Tumorigenicity
Cancer Discov December 1 2015 (5) (12) 1236; DOI: 10.1158/2159-8290.CD-RW2015-199
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • In Vivo CRISPR Screen Identifies FLI1 as Regulator of Effector T Cells
  • Trial Supports Combination Treatment and New Target for Multiple Myeloma
  • Mitochondrial DNA Damage Triggers an IFN-Mediated Immune Response
Show more Research Watch

Glioma

  • Distinct Transitional States of Glial Progenitors Drive Gliomagenesis
  • Unique Molecular Landscapes Distinguish Low- and High-Grade NF1 Gliomas
  • (R)-2HG Inhibits the BCAT Transaminase in IDH-Mutant Glioma
Show more Glioma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement